The more question you ask the more different answers you will get

Similar documents
Insulin Pens - Medical Devices Pipeline Assessment, 2016

Presentation of. Burgdorf, 1 st November 2012

Research and Forecast on China Insulin Market, (Sample)

AN INTRODUCTION TO YPSODOSE FOR THE LARGE-VOLUME INJECTION OF BIOLOGICS

SMARTPILOT FOR YPSOMATE: TRANSFORMING A PROVEN AUTOINJECTOR INTO A FULLY CONNECTED DEVICE

DIABETES CARE DEVICES MARKET IN BRAZIL, RUSSIA, INDIA & CHINA (BRIC)

DEVELOPMENT OF PLATFORM INJECTION DEVICES ADDRESSING HUMAN FACTORS AT AN EARLY STAGE FOR DIFFERENT USER GROUPS

Ypsomed Holding AG Annual Report 2013/14

BRIC DIABETES DRUGS MARKET

Annual Figures 2017/18. Burgdorf, 24 May 2018

Type 1 Diabetes (T1D) Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 Hexa Research

International Operations overview and strategy. Maziar Mike Doustdar EVP International Operations. Slide 1

China Insulin Industry Report, Jan. 2011

ONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE

DBA Design Effectiveness Awards SoloSTAR. A disposable pen injector for insulin

Ypsomed Holding AG Annual Report 2014 / 15

AstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance. Becoming Global Leaders In Diabetes

Noninvasive Glucose Monitors to 2022

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics

Slide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes

Slide 1. Welcome and strategy update. Lars Fruergaard Jørgensen President and CEO

Chronic Care North America update Coloplast Capital Markets Day 2018 Manu Varma, Senior Vice President, Chronic Care Management, NA

Guideline on Health Food Exportation to China

January 30, 2018 Dow Wilson President and Chief Executive Officer

HUMAN FACTORS ENGINEERING OF SELF-INJECTION DEVICES

Slide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO

Eli Lilly and Company Tailored Therapeutics and Diagnostics

Ypsomed Holding AG Annual Report 2015 / 16

Ypsomed Holding AG Annual Report 2012/13

Ypsomed Holding AG Annual Report 2011/12

Delivering Results POSITIONED FOR GROWTH. Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental

Boehringer Ingelheim Biopharmaceuticals in China. Your Reliable Contract Manufacturing Solution Provider

Walgreens (WAG) Analyst: Juan Fabres Fall 2014

An exciting combination in a high growth, high margin Nutrition category. Name of chairman

The dental market. Facts, trends and dynamics.

Patrick J. Sullivan, President & CEO March 7, 2016 Raymond James 37 th Annual Institutional Conference

The Crisis in. Vaccine Development

GLOBAL INSIGHT SERIES. Global Baking Insights: Gluten-Free Bread Consumption

Noninvasive Glucose Monitors Devices, Technologies, Players and Prospects

A New Class of Malaria Drugs: The Coartem Breakthrough from Novartis

Slide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A

Boehringer Ingelheim BioXcellence. Producing Value. Global Contract Manufacturing Excellence

Roche Diagnostics Daniel O Day COO Roche Diagnostics. Société Générale - The Premium Review Conference, Paris December 2, 2011

Putting ALK on the right growth trajectory

Purolite Life Sciences Brand Positioning Catalyst

Boehringer Ingelheim BioXcellence. Producing Value. Global Contract Manufacturing Excellence

ADVANCIA : A TRUE PLATFORM & INNOVATIVE SYSTEM OFFERING EFFICIENT NASAL DOSE DELIVERY

This is a licensed product of Ken Research and should not be copied

GLOBAL NEUROSTIMULATION MARKET

About ACPA... Our Mission...

The Way Ahead Our Three Year Strategic Plan EVERY MOMENT MATTERS

Galvus US NDA Approvable - Overview

Product Information. Straumann CARES Scan & Shape Turn into digital.

Nestlé Investor Seminar 2008

2. Develop teams of four students (there are seven unique roles in ABIG Company).

Product Information. Straumann CARES Scan & Shape Turning into digital solutions.

Annual Report Ypsomed Holding AG 2005/06

H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review

Value growth in Human Nutrition & Health

Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018

Global Prefilled Syringes Market: Trends, Opportunities and Forecasts ( )

Annual Shareholders Meeting

Cowen Investor Conference March confidently live life with ease

LEERINK GLOBAL HEALTHCARE CONFERENCE. Marino Garcia EVP, Chief Strategy Officer February 15, 2017

Scopus. Cancer Research and Treatment Activity Report

CPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018

SAMPLE. Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to Reference Code: GDME0166BDB

Business Contributions to Setting New Research Agendas: Business Platform for Nutrition Research (BPNR)

DIGITAL DIABETES CARE MARKET READY TO TAKE OFF

Welcome to the Full -Year Results Press Conference

Orally Inhaled Corticosteroids to 2022

Boehringer Ingelheim Pharmaceuticals, Inc. & Univision. Making Diabetic Hispanics Healthier

Wednesday 26 th November 2008 The ASX Company Announcements office: Chairman s AGM Address

Shareholder Presentation Annual Meeting 2018

Operational Efficiency:

Chronic illness is a growing market for Novo Nordisk

NOVO NORDISK. Analyst: Recommendation: HOLD DATE: Industry: Drug manufacturers

COMPANY PROFILE. AL SHAMS Group

Autumn Press Conference October 2005

One intelligent solution

ORIENTATION SAN FRANCISCO STOP SMOKING PROGRAM

Taking Health & Nutrition to the NEXT Level

Continued value growth

Infertility Treatment Devices Market by Product (Cryosystem, Imaging System, Incubator, Micromanipulator, Ovum Aspiration Pump, Sperm Analyzer,

PARTNERSHIP & SPONSORSHIP OPPORTUNITIES

DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM

Aiming High Our priorities by 2020 HALFWAY THERE. Our priorities by 2020

Insight bites HEALTH AND WELLNESS IN CHINA TODAY

TABLE OF CONTENTS. HLC102A - Continuous Glucose Monitoring (CGM): Technologies and Global Markets

Your Partner in Healing

Patrick J. Sullivan Chief Executive Officer. January 9, 2018 Investor Presentation

CEO Operational Report. Annual General Meeting 23 October 2013

Straumann reports 4% growth in local currencies (l.c.) in the first nine months of 2010

Global In-Vitro-Fertilization Market: Trends and Opportunities ( )

China Portable Medical Electronic Devices Industry Report, 2010

Because you care about CONSUMERS HEALTH

Cardboard, injections and emotions Service design put in use

One intelligent solution

Transcription:

The more question you ask the more different answers you will get Experience and lessons learned in China Ulrike Bauer Cicor Innovation Insights Symposium Kloten, September 27, 2016

Agenda Introduction to Ypsomed Why is the Chinese market attractive? Challenges and experiences Success factors in China 2 Ypsomed AG B2B in China

Ypsomed Company Overview Founded in 1984 as Disetronic Turnover ~CHF 337 Mio CHF (2015/16) with double digit growth each year over the last 3 years Listed at Swiss Stock Exchange Headquarter and manufacturing in Burgdorf & Solothurn CH Around 1 200 employees in headquarter & affiliates 3 Ypsomed AG B2B in China

Ypsomed solutions make self-care simpler and easier: 2 business fields: B2B & B2C B2B B2C 4 Ypsomed AG B2B in China

Drivers for Self Injection Competition demands differentiation High comfort and safe and easy to use devices increase identification with the medication Improved compliance and therapeutic result 5 Ypsomed AG B2B in China

What means B2B for Ypsomed s business? Ypsomed develops and manufactures customized versions of its self injections platforms directly for pharma companies Devices are delivered from Ypsomed to a central facility of the pharma company Distribution of the devices finally to patients, is part of the distribution of the drug The patient often does not know that his pen injector is made by Ypsomed Ypsomed products are present since long time in Asian countries, but mainly through the distribution by Big Pharma companies Ypsomed s own local Asian activities started with the increasing relevance of local Asian pharma / biotech companies 6 Ypsomed AG B2B in China

Ypsomed Delivery Systems Customer Base Extract Bydureon Pen SoloStar SymlinPen Gansulin Pen Sulin Pen Eperzan (EU), Tanzeum (US) Pen Genotropin Pen Genotropin pre-filled pen GoQuick Nutropin AQ Pen Gonal-F Pen ConviPen Roferon Pen Lupisulin Pen Preotact Pen Biosulin Pen BiomatikPen 2 Ypsopen Polfa Tarchomin Humatro Pen 3 Palatin Autoinjector 7 Ypsomed AG B2B in China

Market Potential in Asia Big Population 8 Ypsomed AG B2B in China

China Rising Middle Class Growing Pharma Market Increased income Rapidly evolving health care system (>90% of population covered) More access to «Western» drugs besides Traditional Chinese Medicine Government supports local drug manufacturers to create jobs and to decrease dependence from imported drugs Generic / biosimilars drugs 9 Ypsomed AG B2B in China

China Rising Middle Class Growing Diabetes Market Changing lifestyle in China leads to increase in diabetes prevalence - Over 100 millions Chinese adults with diabetes - Among patients with diabetes, only 25.8% received treatment for diabetes, and only 39.7% of those treated had adequate glycemic control. 10 Ypsomed AG B2B in China

First Customer in China Tonghua Dongbao 2002: First local Chinese pharma company to launch (Ypsomed) insulin pen in China 2002 11 Ypsomed AG B2B in China

Dongbao Product Lifecycle Management 2006: Metal pen Premium look is important Rough use conditions in China 2010: Spring driven pen injector Dongbao competes against global players (Novo Nordisk, Eli Lilly, Sanofi) 2013: Low cost pen in addition Ypsomed specific development for emerging markets Manufacturing at CMO in China Allows Dongbao to grow in rural areas 12 Ypsomed AG B2B in China

Registration / Business Models / Trade Agreements Requirements from regulatory agency (CFDA) have changed and increased significantly over the last 10 years Started with local registration by pharma customer with very few documents, although Swiss product was imported from abroad Second and third life cycle product still with same setup but requirements for documentation increased Today: Less influence on local authorities by customers possible increased fight against potential corruption Stricter definition of local product and imported product BUT: Requirements and/or leeway often are not clear Increasing complexity also with trying to profit from free trade agreement 13 Ypsomed AG B2B in China

How to deal with constantly changing requirements? European/Swiss companies tend to strive for the proven, right solution How do we find out what the proven right solution is? Especially in constantly changing environment? Look for local advise rather than from other foreign sources Look at the way how others have done it The more questions you ask the more different answers you will get! Breaking the habits and try out the best possible way that you find after a reasonable amount of time and effort for evaluation. Be flexible and be prepared to face setbacks 14 Ypsomed AG B2B in China

Other challenges cultural differences Communication is difficult (language, time difference, really understanding each other) Expectations in a supplier / customer relationship are different - Extremely short reaction time expected - Always highest priority expected - Agreements in contracts are not really considered in daily life Reliable planning is difficult / flexibility is key Negotiations have different rules 15 Ypsomed AG B2B in China

Relationships Yang, Liu (2014): Ost trifft West 16 Ypsomed AG B2B in China

Emotions Yang, Liu (2014): Ost trifft West 17 Ypsomed AG B2B in China

Dealing with Issues Yang, Liu (2014): Ost trifft West 18 Ypsomed AG B2B in China

Express an Opinion Yang, Liu (2014): Ost trifft West 19 Ypsomed AG B2B in China

Party / Celebrate Yang, Liu (2014): Ost trifft West 20 Ypsomed AG B2B in China

China Success Factors Key Account Management Personal relationships on different management levels Half yearly meetings between CEOs Exclusivity for products 21 Ypsomed AG B2B in China

China Success Factors Key Account Management Strengthen relationship with social events 22 Ypsomed AG B2B in China

China Success Factors Key Account Management Marketing support - Training of sales representatives - Marketing / segmentation strategy 23 Ypsomed AG B2B in China

Business Development in China Exhibitions Presence at local exhibitions Networking with other suppliers to the industry 24 Ypsomed AG B2B in China

Business Development in China local presence 2014: Registration of Ypsomed China - Beijing office with today 3 CN employees - Communication in Chinese - Availability in local time zone - On-site meetings on short notice possible - Knowledge of Chinese mentality + 5 to 8 trips from HQ to China Employee in Switzerland with Chinese origin 25 Ypsomed AG B2B in China

Business Development in China Product Strategy Positioning as Swiss high precision devices Products for different segments - Dedicated low cost product design to meet high cost pressure with local contract manufacturing at International CMO - Dedicated shiny premium product to meet Chinese taste in premium segment Brochures in Chinese Internet presence in Chinese 26 Ypsomed AG B2B in China

China Success Factors Business Development Local presence is important Build your reputation / image Offer high quality and position your products accordingly Follow a strategy / focus / and set priorities Expect local competition / file local patents / differentiate Price is important but it is not the only important thing Build up relationships Learn about Guanxi / Culture Be brave within limits that you define for yourself 27 Ypsomed AG B2B in China

Thank you for your attention ulrike.bauer@ypsomed.com V10/ / 18.11.2014